Dapagliflozin news

All news on Dapagliflozin (also known as Farxiga and Forxiga): plants, production capacities, investments and involved companies.

15 September 2026

Eli Lilly presents retatrutide, Foundayo and eloraTZP data at EASD 2026

Phase 3 retatrutide and Foundayo results show large weight and A1C reductions and signals of cardiovascular benefit; Phase 2 eloraTZP and additional Mounjaro/Zepbound analyses also presented.
8 June 2026

Lilly's Foundayo (orforglipron) outperforms oral semaglutide, dapagliflozin and placebo in ACHIEVE trials

Oral GLP‑1 orforglipron reduced A1C and body weight more than oral semaglutide, dapagliflozin or placebo across three Phase‑3 trials; FDA filing planned by end of Q2 2026.

Who will be producing Dapagliflozin in the future?

Find out with chemXplore Alpha

Learn more